Griesheim-près-Molsheim (FR)
{name}
{subtitle}
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
city
~15 mi. (Strasbourg, France, +192 more cities)
facility
Institut de cancérologie Strasbourg Europe (ICANS)
biomarker
ER Positive, +1 more biomarker
condition
Breast Carcinoma
drug
abemaciclib, +1 more drug
drug type
hormone therapy, +1 more type
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~15 mi. (Strasbourg, France, +226 more cities)
facility
Clinique Sainte Anne ( Site 0431)
condition
Prostate Adenocarcinoma
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
city
~15 mi. (Strasbourg, France, +199 more cities)
facility
HUS Hopital Hautepierre ( Site 0445)
condition
Hepatocellular Carcinoma
drug
pembrolizumab
drug type
immunotherapy
Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)
city
~15 mi. (Strasbourg, France, +67 more cities)
facility
Nouvel Hôpital Civil (NHC) ( Site 1018)
condition
Non-Squamous Non-Small Cell Lung Carcinoma, +1 more condition
drug
carboplatin, +5 more drugs
drug type
chemotherapy, +1 more type
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
city
~15 mi. (Strasbourg, France, +105 more cities)
facility
Institut de Cancerologie Strasbourg Europe ( Site 0613)
biomarker
ATM Loss, +62 more biomarkers
condition
Breast Carcinoma, +2 more conditions
drug
olaparib
drug type
targeted therapy
Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002)
city
~15 mi. (Strasbourg, France, +76 more cities)
facility
Nouvel Hôpital Civil (NHC) ( Site 1000)
condition
Non-Small Cell Lung Carcinoma
drug
docetaxel, +1 more drug
drug type
chemotherapy, +1 more type
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET) (MK-6482-015)
city
~15 mi. (Strasbourg, France, +29 more cities)
facility
CHU Strasbourg-Hautepierre-Medecine Interne, Endocrinologie et Nutrition ( Site 0402)
condition
Pancreatic Neuroendocrine Tumor, +1 more condition
drug
belzutifan
drug type
targeted therapy
Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab
city
~15 mi. (Strasbourg, France, +29 more cities)
facility
Hopitaux Universitaires de Strasbourg - Service Oncologie et Hématologie, +1 more facility
condition
Urothelial Carcinoma
drug
avelumab, +4 more drugs
drug type
chemotherapy, +2 more types
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
city
~15 mi. (Strasbourg, France, +27 more cities)
facility
Institut de cancérologie Strasbourg Europe (ICANS) ( Site 1203)
condition
Clear Cell Renal Cell Carcinoma
drug
belzutifan, +4 more drugs
drug type
immunotherapy, +1 more type